Perceptions and current practices of community pharmacists regarding antimicrobial stewardship in Tasmania by Rizvi, T et al.
Vol:.(1234567890)
International Journal of Clinical Pharmacy (2018) 40:1380–1387
https://doi.org/10.1007/s11096-018-0701-1
1 3
RESEARCH ARTICLE
Perceptions and current practices of community pharmacists 
regarding antimicrobial stewardship in Tasmania
Tasneem Rizvi1 · Angus Thompson1 · Mackenzie Williams1 · Syed Tabish Razi Zaidi1,2
Received: 19 February 2018 / Accepted: 20 July 2018 / Published online: 2 August 2018 
© The Author(s) 2018
Abstract
Background Despite increasing interest in antimicrobial stewardship (AMS), little is known about the related practices and 
perceptions of community pharmacists. Objective To develop and validate a questionnaire to measure the current practices 
of, and barriers to community pharmacists’ participation in AMS. Setting Community pharmacists in Tasmania, Australia. 
Method A questionnaire to explore AMS knowledge, current practices and perceptions of community pharmacists was devel-
oped. It was designed after rigorous literature review, expert opinion, and feedback from a group of community pharmacists. 
A convenience sample of 140 Tasmanian community pharmacists was used for this study. Cronbach’s alpha and exploratory 
factor analysis (EFA) were used for reliability and validity. The questionnaire was hosted online, a link to which was sent 
by invitation e-mails, fax and post to community pharmacists in Tasmania, Australia. Main outcome measure Current AMS 
practices, perceived importance, barriers and facilitators of AMS. Results Eighty-five pharmacists responded to the survey 
yielding a response rate of 61%. EFA identified one factor solution for each of three perceptions scales and showed accept-
able reliability. The Cronbach’s alpha of perceived importance-understanding was 0.699, perceived importance-motivating 
was 0.734, perceived support from GPs was 0.890, operational barriers was 0.585, general facilitators was 0.615. Most 
pharmacists reported that they counselled patients on adverse effects (86%), drug interactions (94%), and allergies (96%). 
In contrast, less than half (43%) intervened with prescribers regarding antibiotic selection. Lack of training, lack of access 
to patients’ records, limited interactions with general practitioners and absence of a reimbursement model were major barri-
ers limiting community pharmacists’ participation in AMS. Conclusion The questionnaire was of acceptable reliability and 
validity; a larger study will further contribute in its reliability and validity. Future studies utilising the questionnaire at national 
and international level may provide further insights into the determinants of community pharmacist’s involvement in AMS.
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Impact of findings on practice statements
• An improved understanding of routine practices and 
perceptions of community pharmacists related to anti-
microbial stewardship can assist in the development and 
implementation of antimicrobial stewardship related ini-
tiatives in community settings.
• Community pharmacists are willing and capable of play-
ing an important role in helping optimise antimicrobial 
use by educating patients and effectively interacting with 
prescribers, though a number of barriers may currently 
be limiting their participation.
• Knowledge surrounding current practices and percep-
tions of community pharmacists regarding antimicrobial 
stewardship is limited. Future research into the barriers 
to and facilitators of community pharmacists optimising 
antimicrobial use is required.
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Introduction
Increasing antimicrobial resistance (AMR) is a major 
global threat to human health [1]. If not tackled urgently 
AMR will cause 10 million deaths annually by 2050 [2]. 
Antimicrobial stewardship (AMS) refers to the coordinated 
interventions designed to measure and improve the appropri-
ate use of antimicrobials by promoting the selection of the 
optimal antimicrobial drug, dose, duration of therapy, and 
route of administration [3]. AMS is high on the agenda of 
global health organisations and currently there is an increas-
ing interest in community based AMS initiatives, as this is 
where the majority of antibiotic use occurs, much of which 
is inappropriate [4].
Community pharmacists can play an integral role in AMS 
programs within community settings for various reasons. 
Firstly, pharmacists are delivering value added services 
beyond their traditional dispensing duties [5]. Secondly, they 
are one of the most frequently seen healthcare professionals 
and serve as the first point of contact for seasonal viral res-
piratory tract infections-the most common conditions where 
inappropriate use of antibiotics has been noted [6]. Thirdly, 
community pharmacists often liaise between patients and 
various service providers, and are well positioned to opera-
tionalise any AMS framework. Little is known about the 
current practices of community pharmacists in the developed 
world. An improved understanding of these issues can assist 
in the development and implementation of AMS initiatives 
in community settings. Some of the previous studies were 
conducted in countries where antibiotic prescribing and 
dispensing are neither reimbursed nor well regulated thus 
making the research findings less applicable in developed 
countries [7, 8].
In Australia, approximately 27 million antibiotic prescrip-
tions are dispensed annually [9] and antimicrobial use is 
20% above the average of countries in the Organisation for 
Economic Cooperation and Development [10]. To address 
this issue, the Australian government released its first anti-
microbial resistance strategy in the year 2015 [11]. The 
Australian government-funded National Prescribing Service 
MedicineWise (NPS-MW) is playing an important role to 
reduce antibiotic use in the community raising awareness 
through educational initiatives such as the “resistance fighter 
campaign” and “antibiotic awareness week” [12]. In Aus-
tralia, strict regulatory restrictions exist and antibiotics can-
not be dispensed without a prescription [13]. However, once 
a prescription is issued, it is generally valid for 1 year and 
in many cases prescribing software automatically defaults 
to including a repeat. Furthermore, dispensing software in 
Australian community pharmacies have no interface with 
the prescribing software and therefore, pharmacists cannot 
access a patient’s clinical information or laboratory data 
[13]. This further limits Australian community pharmacists 
participation in AMS initiatives. Little is known about the 
current practices and perceptions of pharmacists working in 
the community sector.
The primary aim of our study was to develop and 
validate a questionnaire to measure the perceptions and 
practices of Australian community pharmacists regard-
ing AMS. A secondary aim was to determine community 
pharmacist’s awareness of and engagement with NPS-
MW’s initiatives designed to reduce AMR. The study was 
conducted in the Australian state of Tasmania, which has 
a population of around 520,000 and a geographical area 
similar to that of the Republic of Ireland. The study find-
ings can help to inform AMS frameworks for community 
pharmacists in Australia.
Ethics Approval
This study received approval from Tasmanian Human Risk 
Ethics Committee (HREC) in April 2016 (H0015673).
Method
Survey development
We generated an item pool based on a thorough literature 
review with key words related to antimicrobial steward-
ship, community, and pharmacists [7, 11, 14–20]. STRZ 
reviewed, modified and organised this item pool according 
to Australian pharmacy practice. A demographic section was 
also introduced at this stage. The questionnaire was then 
reviewed by AT and a section on items related to the NPS-
MW initiatives was included. Following the initial review, 
the questionnaire was edited, based on limited piloting on 
researchers and practising pharmacists working in the Divi-
sion of Pharmacy at the University of Tasmania. The final 
questionnaire is available as supplementary material. A 
Likert-type agreement scale was used for questions around 
current practices and perceptions.
Survey deployment
The questionnaire was hosted online using the Lime  Survey® 
portal. A convenience sample of 140 community pharma-
cists across Tasmania was invited to participate in the study 
via e-mail, fax and post during the first week of May 2016. 
Subsequently copies of questionnaire with a standard invita-
tion letter were faxed and posted to pharmacies where there 
had been no initial response. The invitation letter included 
a web link to the questionnaire, a mobile-enabled scanning 
code (QR code) directing participant to the questionnaire 
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site, and a paper survey with a self-addressed reply paid 
envelope. Two reminders were sent on a fortnightly basis 
after faxing/posting. Participants were offered the chance to 
win one of five gift cards selected by a draw conducted at 
the end of the study.
Data analysis
Exploratory factor analysis (EFA) was used to examine the 
internal structure and construct validity of the perception 
scales. Maximum likelihood technique with the oblique 
rotation was employed. The items having a rotated fac-
tor loading of at least 0.55 or above [21] were retained 
for each factor. Qualitative feedback from the participants 
was discussed amongst the investigators where loadings 
were ambiguous. Cronbach’s alpha was used to determine 
the reliability of individual factors. Qualitative comments 
were analysed using a constant comparative approach to 
identify various themes under the guidance of STRZ with-
out any specific software. Univariate linear regression was 
employed to identify variables and factors associated with 
the participants’ scores on the current AMS practices sec-
tion of the survey. Variables with a p value ≤ 0.20 were 
included in the multivariate linear regression model. All 
statistical analyses were performed using SPSS version 22 
(IBM Inc., Chicago, IL).
Results
Eighty-five of the 140 community pharmacists responded to 
the survey yielding a response rate of 61% with the major-
ity of respondents being female (65%) (Table 1). A wide 
distribution of age and experience was noted among the 
participants ranging from 23 to 70 years and 1–50 years 
respectively. Most participants (80%) had an undergraduate 
pharmacy degree as their highest qualifications.
Validity and reliability of the survey tool
Appendix 1 in “Electronic supplementary material” shows 
the results of EFA and Appendix 2 in “Electronic supple-
mentary material” shows the results of reliability analysis 
including total item statistics. The rotated solution for the 
perceived importance scales showed two factors comprising 
of perceived understanding of AMS and perceived moti-
vating factors of AMS (Cronbach Alpha 0.699 and 0.734 
respectively). The EFA of perceived barriers scale yielded 
a two-factor solution comprising of perceptions regarding 
support from GPs and operational barriers (Appendix 1 
in “Electronic supplementary material”). The Cronbach’s 
alpha of the perceived support from GPs and the operational 
barriers scale was 0.89 and 0.58, respectively. The EFA of 
perceived facilitators scale yielded one-factor solution. The 
Cronbach’s alpha of the general facilitators’ scales was 
0.615. Items on monetary compensation and public image of 
pharmacists’ role in AMS were retained because of a strong 
support from the qualitative feedback on these issues.
Results of the study
Awareness of NPS‑MW initiatives
The majority (63%) of pharmacists knew the term ‘antimi-
crobial stewardship’, although 75% reported an improved 
understanding after reading the provided definition. Most 
respondents were aware of the general (80%) and specific 
(72%) NPS-MW quality initiatives, though less than half 
(45%) were aware of the resources available to them. Around 
a quarter of the respondents reported that they are taking 
more interest (24%) and making more interventions (27%) 
regarding antibiotic use due to the NPS-MW’s initiatives. 
Lastly, nearly half of the participants (53%) reported that 
they would be willing to participate in the future AMS initia-
tives if resources are made available.
Current practices of AMS
Pharmacists frequently contacted prescribers relating to 
allergies, dosing, or drug interactions (Table 2). On the 
Table 1  Demographics of survey respondents
Categories Total (%)
Gender (n = 63)
 Female 41 (65%)
 Male 22 (35%)
Age (n = 62)
  21–30 10 (16%)
  31–40 21 (34%)
  41–50 14 (23%)
  51 and above 17 (27%)
Experience as community pharmacist (n = 64)
 Less than 10 years 18 (28%)
 10–19 years 15 (23%)
 20–29 years 13 (20%)
 30 years or more 18 (28%)
Education (n = 65)
 Bachelor’s degree in Pharmacy 52 (80%)
 Master’s degree in Pharmacy 3 (5%)
 Doctorate degree in Pharmacy 3 (5%)
 Other 7 (10%)
Location (n = 65)
 Metro 40 (62%)
 Rural 25 (38%)
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contrary, pharmacists less commonly contacted prescribers if 
they considered the choice of antibiotic to be inappropriate.
Respondents indicated that they were referring patients 
to see GPs if they suspected an infectious presentation 
that might need an antibiotic prescription, but where 
this was not the case Pharmacists reported that they 
were invariably managing patients by offering over the 
counter medicines (95.8%). Pharmacists were commonly 
ascertaining the need for an antibiotic when a patient pre-
sented a repeat prescription (82.9%).
Perceptions and association with AMS practices
Most pharmacists agreed that AMS programs in commu-
nity pharmacy would lead to a reduction in inappropri-
ate antibiotic use and the costs associated with manag-
ing infections (Table 3). Similarly, pharmacists believed 
Table 2  Current AMS practices of Tasmanian community pharmacists
Current practices measured on a scale of 1–5, where 1 = do not practice at all and 5 = practice all the time
n Number of participants, IQR inter quartile range
Scale and items Participant’s response, 
%
Median (IQR)
Scoring ≤ 3 Scoring ≥ 4
Current AMS practices
 Providing clear messages on expected side effects (n = 72) 13.9 86.1 4 (4–5)
 Providing clear messages what should be done if patient experience side effect (n = 72) 22.2 77.8 4 (4–5)
 Contacting the prescriber if the patient is allergic to the prescribed antibiotic (n = 72) 1.4 98.6 5 (5–5)
 Contacting the prescriber if the antibiotic dose/frequency is too high or too low (n = 71) 14.1 85.9 5 (4–5)
 Contacting the prescriber if the prescribed antibiotic involves a drug interaction (n = 70) 2.9 97.1 5 (5–5)
 Contacting the prescriber if the choice of antibiotic may not be optimal (n = 71) 53.5 46.5 3 (2–4)
 Recommending OTC/self-care treatment to patients with symptoms of infection not needing antibi-
otics (n = 71)
4.2 95.8 5 (4–5)
 Referring patients to a general practitioner when symptoms are suggestive of an infection (n = 69) 1 99 5 (5–5)
 Providing advice when it would be appropriate to use the repeat (n = 70) 17.1 82.9 4 (4–5)
 Discussing with patient to determine if it is appropriate for them to use the presented repeat (n = 72) 30.6 69.4 4 (3–5)
Table 3  Perceived importance and barriers to participate in AMS in community pharmacy
Perceived importance and perceived barriers were measured on a scale of 1–7, where 1 = strongly disagree and 7 = strongly agree
n Number of participants, IQR inter quartile range
Scales and items Participant’s response, % Median (IQR)
Scoring ≤ 4 Scoring ≥ 5
Perceived importance of AMS-understanding of the role
 Community pharmacist can play an important role in AMS (n = 68) 2.9 97.1 7 (5–7)
 AMS will reduce health care costs associated with infections (n = 68) 21.6 78.4 7 (5–7)
 AMS will reduce inappropriate antibiotic use (n = 68) 17.6 82.4 5 (5–7)
Perceived importance of AMS-motivating forces
 AMS will enhance the public image of pharmacists (n = 67) 20.9 79.1 6 (5–7)
 AMS will enhance the job satisfaction of pharmacists (n = 67) 17.9 82.1 6 (5–7)
Perceived barriers of AMS-operational barriers
 I do not have the required training to participate in AMS (n = 66) 63.6 36.4 4 (3–5)
 I do not have enough time to participate in AMS (n = 64) 75 25 3 (3–5)
 Limited access to patient record to review the appropriateness of antibiotic prescriptions (n = 65) 4.6 95.4 6 (5–7)
 There aren’t any standard guidelines to implement AMS (n = 62) 33.9 66.1 5 (4–6)
Perceived barriers of AMS-perceived support from GPs
 GPs are not receptive to pharmacists intervening on the choice of antibiotic (n = 63) 34.9 65.1 5 (5–6.25)
 GPs are not receptive to pharmacists intervening on the dose and dosage form of antibiotic (n = 64) 64.1 35.9 3 (3–6)
 GPs are not receptive to pharmacists intervening on the duration of antibiotic (n = 62) 75.8 24.2 3 (3–6)
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that they could play an important role in implementing 
AMS initiatives and their participation in AMS programs 
would lead to a better public image and enhanced job 
satisfaction. Pharmacists also indicated that the lack of 
access to patients’ medical records and objective labo-
ratory information limited their participation in AMS. 
Pharmacists also felt that GPs do not welcome their 
intervention regarding choice of antimicrobial prescrip-
tion (Median = 5, IQR 5–6.25 Scale 1–7). On the con-
trary, interventions related to the dose, duration or dosage 
form of antibiotics were perceived as welcomed by GPs. 
Pharmacists were mostly neutral about the lack of train-
ing as a barrier to their participation in AMS. Likewise, 
most of them did not consider lack of time as a barrier 
in their AMS role (Table 3). Facilitators related to public 
awareness campaigns, collaboration with GPs, access to 
antibiotic guidelines and patients’ clinical and laboratory 
data, were all considered as most helpful in increasing 
pharmacists’ AMS involvement (Table 4).
The univariate linear regression analysis identified 
three variables that showed some degree of association 
with the total scores for the AMS practices section of the 
survey (p value ≤ 0.2). The three variables were willing-
ness to participate in the future AMS initiatives, total 
scores of general facilitators scale and perceived impor-
tance scale. The multivariate linear regression analysis 
did not identify any of these variables having a significant 
association with the AMS practices of the community 
pharmacists (Table 5).
Qualitative feedback
Qualitative comments were analysed using a constant com-
parative approach to identify various themes under the guid-
ance of STRZ. Pharmacists showed great interest in provid-
ing qualitative feedback via free text comments. The main 
themes from the qualitative feedback were contextual limi-
tations of community pharmacists, improper use of repeat 
prescriptions, need of public awareness, lower than recom-
mended dose of antibiotics in children and impact of AMS 
on business model of pharmacy. Software was not used for 
qualitative analysis. Details of these comments are presented 
as Table 6.
Discussion
We report the development and validation of the first ques-
tionnaire to measure the current practices and perceptions 
of AMS amongst Australian community pharmacists. The 
mixed method approach of using EFA, expert opinion 
and qualitative feedback to validate the survey tool was 
found useful in retaining important items for each sec-
tion, yet reducing the size of the questionnaire to a man-
ageable length. The three perception scales demonstrated 
Table 4  Perceived facilitators of AMS in community pharmacy settings
Perceived facilitators measured on a scale of 1–5, where 1 = Unhelpful and 5 = most helpful
n Number of participants, IQR Inter quartile range
a Items not loaded on any factor but retained based on qualitative analysis as participants were very vocal about the issues covered by these items
Scales and items Participant’s response, % Median (IQR)
Scoring ≤ 3 Scoring ≥ 4
Perceived facilitators of AMS-General facilitators
 Increased provision of education activities regarding AMS (n = 65) 6.2 93.8 5 (4–5)
 Better collaboration with local GP practices (n = 65) 1.5 98.5 5 (4–5)
 Clarifications of the duties of pharmacists’ professional organizations (n = 63) 27 73 4 (3–5)
 Better access to patient’s clinical and laboratory data (n = 64) 7.8 92.2 5 (4–5)
Perceived facilitators of AMS-operational  facilitatorsa
 Public awareness initiatives highlighting community pharmacists in AMS (n = 66) 10.6 89.4 5 (4–5)
 Monetary compensation for the time involved in AMS programs (n = 64) 18.8 81.2 4 (4–5)
Table 5  Multivariate linear 
regression analysis: predictors 
of Tasmanian Community 
Pharmacists’ participation in 
AMS (n = 59)
Predictor Unstand-
ardised β
Standardised β P value 95% CI range
Willingness to participate in future AMS initiatives 0.13 0.05 0.07 − 0.56–0.82
Total scores on the perceived importance scale 0.53 0.25 0.20 − 0.06–1.12
Total scores on the general facilitators scale 0.46 0.17 0.70 − 0.25–1.18
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reasonable internal validity as evident from the results 
of EFA and an acceptable reliability demonstrated by a 
Cronbach’s alpha of > 0.5 [21]. Khan et al. [7], Erku [8] 
and a recent study by Sarwar et al. [22] have surveyed 
Malaysian, Ethiopian and Pakistani community pharma-
cists about AMS respectively. The contexts of pharmacy 
practice in these countries are significantly different to 
those found in most Western countries, including Aus-
tralia where antibiotics are available only with a valid 
prescription. Additionally, based on the reported results, 
the authors have not conducted a formal exploratory 
factor analysis to examine the internal structure of the 
questionnaire.
Principal findings of the pilot survey
Our findings highlight that Australian pharmacists contrib-
ute to triaging common infectious presentations, determin-
ing those conditions that may require medical attention and 
those which are minor ailments amenable to self-care or 
management with over the counter medicines. This par-
ticular role of community pharmacists is not as widely 
appreciated in Australian settings as it has been in other 
countries. For example, provision of advice for minor ail-
ments is considered a reimbursable activity in the United 
Kingdom [23]. We found that pharmacists were less com-
fortable about intervening with the choice of antibiotics or 
advising patients on the use of repeat prescriptions when 
Table 6  Qualitative feedback from the Tasmanian Community Pharmacists
Theme Example statements
Contextual limitations Unlike hospital setting, implementation of AMS is certainly a challenge in the community. GPs prescribe antibiotics 
due to the pressure of patients. Are there any ID consultants involved in community AMS? Who is going to give 
approval and decide the duration?
Not sufficient information about ailment or patient to make a call about appropriateness of antibiotic
Until we are provided full history, pathology and diagnosis, very difficult to implement
It is not always easy to determine what infection is being treated in a patient, as we have not made the diagnosis and if 
the patient can communicate this appropriately then ensuring the most suitable antibiotic can be difficult as it may be 
specific to a sputum sample, culture etc. This could be a hurdle in AMS
I think you cannot have an AMS program in community pharmacies without any prior agreement with the prescribing 
doctors for those pharmacies, otherwise will cause client confusion, and worsen the relationship with doctors. Also 
considering that pharmacists lack diagnostics skills, it is the role of the doctor to determining the need for antibiotic 
and not the pharmacist to question the doctor’s decision
Increase public aware-
ness
I always explain the expected duration whether it is less than or more than an initial supply and discourage the use of 
repeats weeks after the original has been filled
Many patients still expect to come away from a doctor’s appointment with an antibiotic prescription, especially for a 
child with respiratory symptoms or middle ear infection-despite these often being self-limiting
I believe that more public education is necessary for people to understand when antibiotics are appropriate and when 
they are not
Policy support to 
define pharmacist’s 
role
Pharmacists are definitely in an ideal position to be able to intervene when inappropriate antibiotic use is evident—
however, the means by which the program is introduced is essential
Pharmacists already have the knowledge and correct attitude to reduce antibiotic misuse, we just need the authority
I genuinely think most people are unaware of what pharmacists are able to do and what we are supposed to do
Improper use of repeat 
prescriptions
A good start would be modifying the prescribing software to force prescribers to actually decide whether a repeat is 
necessary or not, rather than automatically defaulting to a repeat for every patient
I think that antibiotic scripts should have a 2 week expiry—unless for a long-term condition. It would save repeats 
being saved and presented at other times …
Lower than recom-
mended dose of anti-
biotics in children
Often once a week have to call doctor to adjust dose of antibiotic for children as often under dosed. Often doctors don’t 
tell if they need repeat or not
Notice lower then recommended children antibiotic doses, when double check with doctors they prefer to use lower 
doses anyway
Impact of AMS on the 
business model of 
pharmacy
There is absolutely a need to have better remuneration for pharmacies involved in AMS programs—if the pharma-
cist involved is effectively performing their role, they may in fact be reducing script volume of antibiotics and thus 
negatively affecting the pharmacy’s takings. For instance in a pharmacist encourages a doctor to cancel a prescription 
for an antibiotic that is unnecessary, the pharmacy is missing out on (for example) a $10 sale. The whole process of 
contacting the GP, then discussing the decision with the patient may take up 15–20 min of the pharmacist’s time and 
ultimately the pharmacy is down $10
We are time poor, with rapidly reducing income with health dept. and govt. who do not respect us. But still expect us to 
enable initiatives with little or no remuneration
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compared to other activities such as intervening on the dose 
and duration of antibiotics and counselling patients regard-
ing the adverse effects of antibiotics. Qualitative comments 
further provided clarification about the contextual limita-
tions of the Australian community pharmacy practice in 
determining the appropriateness of antibiotics or contacting 
GPs for interventions related to paediatric antibiotic dosing. 
These findings are not surprising, as community pharma-
cists in Australia do not have access to a patient’s clinical 
and laboratory data. Additionally, unlike the UK and most 
of Scandinavia, community pharmacies in Australia do not 
operate within a healthcare network which may be limiting 
one-on-one interaction between GPs and pharmacists [24].
Most pharmacists in this study rated the importance 
of AMS highly, considering it a source of motivation and 
learning, potentially enhancing the public image of the 
profession. Likewise, pharmacists also believed that AMS 
programs in the community will reduce inappropriate anti-
biotic use and healthcare costs. Our results are consistent 
with the study of Burger et al. [25] where the majority of 
respondents indicated that AMR is a worldwide problem 
and pharmacists have an important role to play in tackling 
this problem. The perceived barriers pharmacists reported 
in the study included lack of access to patient’s clinical and 
laboratory data and lack of co-operation from the GP when 
the community pharmacist intervenes regarding selection of 
antibiotics, both of which can be inter-related. Our findings 
are in line with a systematic review by the National Insti-
tute of Health Research, England [26] which reported that 
barriers to implementing AMS include lack of resources, 
patients’ expectations regarding antibiotics and the influ-
ence of colleagues on the selection of antibiotics. Most of 
the respondents believed that educational activities targeted 
towards pharmacists and patients will enable them to per-
form AMS duties efficiently. Similarly, most of the commu-
nity pharmacists suggested improved collaboration with pre-
scribers and patients’ clinical and laboratory data would be 
helpful and enable them to better participate in AMS. This is 
consistent with the updated statement from the International 
Pharmaceutical Federation which stressed the importance of 
pharmacist and public educational initiatives in implement-
ing AMS [27].
Awareness of AMS and national quality initiatives
The findings of the pilot study identified a gap between AMS 
awareness and utilisation of available resources by commu-
nity pharmacists. More efforts to engage pharmacy students, 
interns and pharmacists are required to develop community 
pharmacist’s competency in AMS. The majority of respond-
ents were not regularly referring to the resources and activi-
ties of NPS-MW. Almost half of the respondents reported 
that they are not currently utilising the educational resources 
available to them but would definitely employ these if they 
get its easy access. Globally an increasing number of learn-
ing and training courses and toolkits are offered by public 
and private organisations, institutions and countries [28–31], 
some of which are free web-based online courses and others 
are inter-professional curriculums to increase pharmacists’ 
competency in AMS. There is a clear a need for such initia-
tives to help bridge this AMS knowledge gap for Australian 
community pharmacists.
Limitations and strengths
The findings of our study should be interpreted with some 
caution. We only examined the views of pharmacists from 
one Australian state (Tasmania) and the views may not be 
generalizable to all Australian community pharmacists. Given 
the traditionally poor response rate with survey studies, we 
utilised a convenient sample of pharmacists drawn from a 
pool whose details are on file in the Division of Pharmacy, 
at the University of Tasmania, and this may further limit the 
generalisability of our findings. In contrast, a few specific 
strengths of the study should also be highlighted. To the best 
of our knowledge, this is the only study to report the develop-
ment and validation of a questionnaire to measure commu-
nity pharmacists’ perceptions of, and barriers to AMS in the 
community setting. We employed a robust process combining 
quantitative and qualitative data while supplementing it with 
expert opinion to develop and refine the questionnaire.
Conclusion
The newly developed questionnaire to measure pharmacists’ 
perceptions of and barriers to, AMS in community settings 
demonstrated acceptable reliability and validity. Pharma-
cists were supportive of their involvement in the AMS, 
though they highlighted some important barriers limiting 
this involvement. A future Australia-wide study, employing 
the newly developed tool, will provide more data to examine 
the questionnaire’s reliability and validity while providing 
further insights into the perceptions and practices of com-
munity pharmacists regarding AMS at a national level.
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